The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...

Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part of its 2024–2025 campaign, a 45 percent ...

Onradivir significantly shortens recovery time in adults with uncomplicated influenza A. Read more. Learn more.

An 82-year-old on haemodialysis tests HIV-positive 7 months in, only for PCR to be negative, implicating flu shot antibody ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...